ES2537792T3 - Compuestos anti-amnésicos y composiciones farmacéuticas que los contienen - Google Patents

Compuestos anti-amnésicos y composiciones farmacéuticas que los contienen Download PDF

Info

Publication number
ES2537792T3
ES2537792T3 ES09159440.8T ES09159440T ES2537792T3 ES 2537792 T3 ES2537792 T3 ES 2537792T3 ES 09159440 T ES09159440 T ES 09159440T ES 2537792 T3 ES2537792 T3 ES 2537792T3
Authority
ES
Spain
Prior art keywords
carbon atoms
group
represent
hydrogen atom
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09159440.8T
Other languages
English (en)
Inventor
Marc Verleye
Marie-Emmanuelle Le Guern
Jean-Marie Gillardin
Bernard Hublot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocodex SAS
Original Assignee
Biocodex SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocodex SAS filed Critical Biocodex SAS
Application granted granted Critical
Publication of ES2537792T3 publication Critical patent/ES2537792T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilización de al menos un compuesto de la siguiente fórmula (II):**Fórmula** en la que: - R1, R2, R3, y R4, idénticos o diferentes, representan un átomo de hidrógeno, un átomo de halógeno, especialmente elegido entre F, CI, Br, o I, un grupo hidroxi, o un grupo alcoxi de 1 o 2 átomos de carbono; - R5 y R6, idénticos o diferentes, representan un átomo de hidrógeno, un grupo alquilo o cicloalquilo de 1 a 6 átomos de carbono, o un grupo arilo de 6 átomos de carbono cuyo núcleo aromático está eventualmente sustituido con uno o varios átomos de halógeno o uno o varios grupos hidroxi, alcoxi de 1 o 2 átomos de carbono, trifluorometilo o nitro; - R9 y R10, idénticos o diferentes, representan un átomo de hidrógeno, un grupo hidroxi, o un grupo alquilo o hidroxialquilo de 1 a 3 átomos de carbono; o de al menos una sal farmacéuticamente aceptable del mismo, para la preparación de un medicamento destinado a la prevención o al tratamiento de los trastornos mnésicos, en particular de los trastornos amnésicos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8

Claims (1)

  1. imagen1
    imagen2
ES09159440.8T 2008-05-06 2009-05-05 Compuestos anti-amnésicos y composiciones farmacéuticas que los contienen Active ES2537792T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0853003 2008-05-06
FR0853003A FR2930891B1 (fr) 2008-05-06 2008-05-06 Composes anti-amnesiants et compositions pharmaceutiques les comprenant

Publications (1)

Publication Number Publication Date
ES2537792T3 true ES2537792T3 (es) 2015-06-12

Family

ID=40016061

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09159440.8T Active ES2537792T3 (es) 2008-05-06 2009-05-05 Compuestos anti-amnésicos y composiciones farmacéuticas que los contienen

Country Status (4)

Country Link
US (1) US20090298817A1 (es)
EP (1) EP2116247B1 (es)
ES (1) ES2537792T3 (es)
FR (1) FR2930891B1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3051114B1 (fr) * 2016-05-11 2019-09-27 Biocodex Composes pour le traitement de la maladie d'alzheimer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1745786A (en) * 1929-04-12 1930-02-04 Western Union Telegraph Co Pneumatic dispatch carrier
DE1670772C3 (de) * 1966-11-24 1978-04-20 Hoechst Ag, 6000 Frankfurt 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
US5470951A (en) 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
CA2221637A1 (en) 1995-06-06 1996-12-12 Steven M. Ruben Human g-protein receptor hcegh45
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
DE10119862A1 (de) 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
JP4337447B2 (ja) * 2003-07-09 2009-09-30 ソニー株式会社 フラットディスプレイ装置及び集積回路
US20070000393A1 (en) * 2004-11-10 2007-01-04 Lam Raymond H Electric grill
CA2612478A1 (en) * 2005-06-27 2007-01-04 F. Hoffman-La Roche Ag 8-alk0xy-4-methyl-3, 4-dihydr0-quinaz0lin-2-yl amines and their use as 5-ht5a receptor ligands
FR2888748B1 (fr) * 2005-07-19 2007-10-12 Biocodex Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
US20080039453A1 (en) * 2006-03-20 2008-02-14 David Putman Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2007109289A1 (en) * 2006-03-20 2007-09-27 Xytis Inc. Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use

Also Published As

Publication number Publication date
FR2930891A1 (fr) 2009-11-13
EP2116247B1 (fr) 2015-03-04
EP2116247A3 (fr) 2010-01-06
US20090298817A1 (en) 2009-12-03
EP2116247A2 (fr) 2009-11-11
FR2930891B1 (fr) 2010-09-24

Similar Documents

Publication Publication Date Title
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
CO6351726A2 (es) Compuestos pirazolicos 436
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
AR110443A1 (es) Inhibidores de histona metiltransferasas
UY29346A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
CU20130116A7 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
AR074801A1 (es) Monocarbamas y composiciones farmaceuticas que los contienen
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
AR097931A1 (es) Derivados de diazacarbazol como ligandos de tau para pet
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
IN2014DN07283A (es)
MA39043B1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
AR067770A1 (es) Derivados de tiazol y ditiazol para el tratamiento de diabetes
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
AR078722A1 (es) Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol